Denali Therapeutics Inc.
DNLI
$20.62
-$0.09-0.41%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -1.89% | 3.78% | 12.36% | 8.61% | -13.76% |
| Gross Profit | 1.89% | -3.78% | -12.36% | -8.61% | 13.76% |
| SG&A Expenses | 31.28% | 42.23% | 28.07% | 16.31% | 21.36% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.79% | 11.57% | 15.76% | 10.08% | -7.56% |
| Operating Income | -5.79% | -11.57% | -15.76% | -10.08% | 7.56% |
| Income Before Tax | -12.00% | -18.39% | -25.34% | -30.62% | 3.98% |
| Income Tax Expenses | 50.00% | -- | -- | -- | 126.67% |
| Earnings from Continuing Operations | -12.02% | -18.39% | -25.34% | -30.62% | 3.95% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.02% | -18.39% | -25.34% | -30.62% | 3.95% |
| EBIT | -5.79% | -11.57% | -15.76% | -10.08% | 7.56% |
| EBITDA | -5.00% | -10.46% | -14.27% | -9.44% | 7.98% |
| EPS Basic | -8.58% | -16.35% | -23.43% | -13.97% | 21.93% |
| Normalized Basic EPS | -4.35% | -16.34% | -23.43% | 5.86% | 29.63% |
| EPS Diluted | -8.58% | -16.35% | -23.43% | -13.97% | 21.93% |
| Normalized Diluted EPS | -4.35% | -16.34% | -23.43% | 5.86% | 29.63% |
| Average Basic Shares Outstanding | 3.16% | 1.75% | 1.55% | 14.60% | 23.03% |
| Average Diluted Shares Outstanding | 3.16% | 1.75% | 1.55% | 14.60% | 23.03% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |